Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

40 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 18: Visit 3 (Week 5) RLS Episode 6

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 18: Visit 3 (Week 5) RLS Episode 6 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 19: Visit 3 (Week 5) RLS Episode 7

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 19: Visit 3 (Week 5) RLS Episode 7 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 20: Visit 3 (Week 5) RLS Episode 8

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 20: Visit 3 (Week 5) RLS Episode 8 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 13: Visit 3 (Week 5) RLS Episode 1

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 13: Visit 3 (Week 5) RLS Episode 1 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 14: Visit 3 (Week 5) RLS Episode 2

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 14: Visit 3 (Week 5) RLS Episode 2 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 17: Visit 3 (Week 5) RLS Episode 5

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 17: Visit 3 (Week 5) RLS Episode 5 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 6: Visit 8 (Week 15) RLS Episode 5

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 6: Visit 8 (Week 15) RLS Episode 5 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 5 Visit 8 (Week 15) RLS Episode 4

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 5: Visit 8 (Week 15) RLS Episode 4 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 9: Visit 8 (Week 15) RLS Episode 8

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 9: Visit 8 (Week 15) RLS Episode 8 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 8: Visit 8 (Week 15) RLS Episode 7

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 8: Visit 8 (Week 15) RLS Episode 7 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 3 Visit 8 (Week 15) RLS Episode 2 - Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 3 Visit 8 (Week 15) RLS Episode 2

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 3: Visit 8 (Week 15) RLS Episode 2 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862 - Part 4: Visit 8 (Week 15) RLS Episode 3

- 12/06/2017 - 1 Formulário, 3 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: General Information, PRN Subject Diary, Study Medication
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 4: Visit 8 (Week 15) RLS Episode 3 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial